GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » Price-to-Owner-Earnings

MDXXF (Pharmala Biotech Holdings) Price-to-Owner-Earnings : (As of Apr. 14, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Pharmala Biotech Holdings Price-to-Owner-Earnings?

As of today (2025-04-14), Pharmala Biotech Holdings's share price is $0.1101. Pharmala Biotech Holdings does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Pharmala Biotech Holdings's Price-to-Owner-Earnings or its related term are showing as below:


MDXXF's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 30.005
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-04-14), Pharmala Biotech Holdings's share price is $0.1101. Pharmala Biotech Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2024 was $-0.00. Therefore, Pharmala Biotech Holdings's PE Ratio (TTM) for today is At Loss.

As of today (2025-04-14), Pharmala Biotech Holdings's share price is $0.1101. Pharmala Biotech Holdings's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.00. Therefore, Pharmala Biotech Holdings's PE Ratio without NRI for today is At Loss.


Pharmala Biotech Holdings Price-to-Owner-Earnings Historical Data

The historical data trend for Pharmala Biotech Holdings's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings Price-to-Owner-Earnings Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24
Price-to-Owner-Earnings
- - - -

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 Aug24 Nov24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pharmala Biotech Holdings's Price-to-Owner-Earnings

For the Biotechnology subindustry, Pharmala Biotech Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmala Biotech Holdings's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's Price-to-Owner-Earnings falls into.


;
;

Pharmala Biotech Holdings Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Pharmala Biotech Holdings's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.1101/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmala Biotech Holdings  (OTCPK:MDXXF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Pharmala Biotech Holdings Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmala Biotech Holdings Business Description

Traded in Other Exchanges
Address
1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.